New study tracks pregnancy safety of Rare-Disease drug

NCT ID NCT05040373

Recruiting now Knowledge-focused Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 09, 2026 · Updated 23 times

Summary

This study follows up to 10 women who were exposed to the drug patisiran-LNP during pregnancy to see how their pregnancies and babies turn out. It does not test a new treatment but collects real-world information on birth defects and pregnancy complications. The goal is to better understand the safety of patisiran in pregnant women with hATTR amyloidosis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Trial Site
RECRUITING

Iowa City, Iowa, 52242, United States
Clinical Trial Site
RECRUITING

Nantes, France
Clinical Trial Site
RECRUITING

Münster, Germany
Clinical Trial Site
RECRUITING

Pavia, Italy
Clinical Trial Site
RECRUITING

Groningen, Netherlands
Clinical Trial Site
RECRUITING

Lisbon, Portugal
Clinical Trial Site
RECRUITING

Madrid, Spain

Conditions

Explore the condition pages connected to this study.

HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS POLYNEUROPATHY